Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation

• Main Authors: Yang-Qi Pan (Author), Lu-Shen Jin (Author), Sang Qian (Author), Ting Jiang (Author), Zhe-Ning Wang (Author), Yi-Lian Chen (Author), Yi-Xuan Qiu (Author), Yi-Hao Wu (Author), Jia-Yang Fu (Author), Ling Li (Author), Yuan-Nan Lin (Author), Yue-Chun Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and aim: Rivaroxaban is an emerging oral anticoagulant for postoperative anticoagulation after percutaneous left atrial appendage closure (LAAC). Because a once-daily dosing regimen of rivaroxaban causes fluctuations in the drug plasma concentration, we studied the feasibility and safety...